Keywords: Crohn's disease, Remicade, Humira, Market forecasts, Decision Resources

Uptake of biosimilars will see Remicade and Humira sales decline in 2017

Article | 26 September 2012

Print This

The TNF-alpha inhibitors infliximab (Janssen Biotech/Merck/Mitsubishi Tanabe’s Remicade) and adalimumab (Abbott/Eisai’s Humira) dominated ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in